Hybolin-Improved Alternatives Compared
Hybolin-Improved | Palbociclib | Pembrolizumab |
|
---|
Hybolin-Improved (nandrolone) | Palbociclib | Pembrolizumab |
|
---|---|---|---|
Prescription only
Prescribed for Anemia Due to Chronic Kidney Disease, Breast Cancer. Hybolin-Improved may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Liposarcoma, Breast Cancer, Breast Cancer - Male. palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Bladder Cancer, Breast Cancer, Cervical Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
|
More about (nandrolone) | More about Palbociclib | More about Pembrolizumab | |
Ratings & Reviews | |||
Be the first to share your experience with this drug. |
Palbociclib has an average rating of 6.9 out of 10 from a total of 98 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 29% reported a negative effect. |
Pembrolizumab has an average rating of 4.6 out of 10 from a total of 235 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 54% reported a negative effect. |
|
Drug Class | |||
Side Effects | |||
See also: Hybolin-Improved side effects in more detail. |
See also: palbociclib side effects in more detail. |
See also: pembrolizumab side effects in more detail. |
|
Generic Availability | |||
N/A |
N/A |
N/A |
|
Pricing and Coupons * Prices are without insurance | |||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Dosage Forms Available | |||
N/A |
N/A |
N/A |
|
Brand Names | |||
N/A |
Ibrance | Keytruda | |
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||
N/A |
29 hours |
624 hours |
|
CSA Schedule ** View glossary of terms | |||
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category | |||
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
|
Drug Interactions | |||
A total of 85 drugs are known to interact with Hybolin-Improved:
|
A total of 459 drugs are known to interact with palbociclib:
|
A total of 16 drugs are known to interact with pembrolizumab:
|
|
Alcohol/Food/Lifestyle Interactions | |||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
Disease Interactions | |||
First Approval Date | |||
N/A |
N/A |
N/A |
|
WADA Class View World Anti-Doping Agency classifications. | |||
N/A |
N/A |
||
More Information | |||
Patient resources | |||
N/A |
|||
Professional Resources | |||
N/A |
|||
Related Treatment Guide | |||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.